open access

Vol 13, No 6 (2017)
Research paper
Published online: 2018-01-04
Get Citation

Metachronic cancers among women with brest cancer and BRCA1 mutation

Maksymilian Kruczała, Marek Jasiówka, Elżbieta Marczyk, Paweł Blecharz
DOI: 10.5603/OCP.2017.0039
·
Oncol Clin Pract 2017;13(6):264-267.

open access

Vol 13, No 6 (2017)
ORIGINAL ARTICLES
Published online: 2018-01-04

Abstract

Background: Breast cancer is the most common malignancy among women worldwide and in Poland. Mutation in BRCA1 gene is responsible for approximately 6% breast cancers in Poland diagnosed before the age of 50. BRCA1 dependent cancers occur early and frequently are bilateral. The purpose of this work was to evaluate the frequency of metachronic cancers in the population of 42 patients with breast cancer and BRCA1 mutation. Material and methods: Medical histories of 196 patients with confirmed mutation in BRCA1 gene consulted in the Krakow Branch of the Maria Skłodowska Curie Memorial Cancer Centre and Institute of Oncology between 2005 and 2016 were analyzed. Medical histories of 42 patients with breast cancer were chosen for further analysis in the aspect of metachronic cancers. Results: During the observation period (mean of 10 years) 21 (50%) metachronic cancers were diagnosed, breast cancer was the most common one occurring in 16 (38%) cases. Additionally, 2 synchronic breast cancers occurred, and in 3 other cases breast cancer was the metachronic one. Conclusions: In light of the obtained results, the medical community should be aware of the scale of the problem of metachronic cancers among the patients with diagnosed BRCA1 mutation. Intensified surveillance for early detection of metachronic cancer and perspective of prophylactic mastectomy and adnexectomy for women treated from BRCA1 positive breast cancer should be considered.

Abstract

Background: Breast cancer is the most common malignancy among women worldwide and in Poland. Mutation in BRCA1 gene is responsible for approximately 6% breast cancers in Poland diagnosed before the age of 50. BRCA1 dependent cancers occur early and frequently are bilateral. The purpose of this work was to evaluate the frequency of metachronic cancers in the population of 42 patients with breast cancer and BRCA1 mutation. Material and methods: Medical histories of 196 patients with confirmed mutation in BRCA1 gene consulted in the Krakow Branch of the Maria Skłodowska Curie Memorial Cancer Centre and Institute of Oncology between 2005 and 2016 were analyzed. Medical histories of 42 patients with breast cancer were chosen for further analysis in the aspect of metachronic cancers. Results: During the observation period (mean of 10 years) 21 (50%) metachronic cancers were diagnosed, breast cancer was the most common one occurring in 16 (38%) cases. Additionally, 2 synchronic breast cancers occurred, and in 3 other cases breast cancer was the metachronic one. Conclusions: In light of the obtained results, the medical community should be aware of the scale of the problem of metachronic cancers among the patients with diagnosed BRCA1 mutation. Intensified surveillance for early detection of metachronic cancer and perspective of prophylactic mastectomy and adnexectomy for women treated from BRCA1 positive breast cancer should be considered.
Get Citation

Keywords

breast cancer, BRCA1 mutation, metachronic cancers

About this article
Title

Metachronic cancers among women with brest cancer and BRCA1 mutation

Journal

Oncology in Clinical Practice

Issue

Vol 13, No 6 (2017)

Article type

Research paper

Pages

264-267

Published online

2018-01-04

DOI

10.5603/OCP.2017.0039

Bibliographic record

Oncol Clin Pract 2017;13(6):264-267.

Keywords

breast cancer
BRCA1 mutation
metachronic cancers

Authors

Maksymilian Kruczała
Marek Jasiówka
Elżbieta Marczyk
Paweł Blecharz

References (25)
  1. http://gco.iarc.fr/today/.
  2. Didkowska J, Wojciechowska U, Zatoński W. Nowotwory złośliwe w Polsce w 2011 roku. Centrum Onkologii-Instytut, Warszawa 2013: 12.
  3. Wojciechowska U, Didkowska J, Zatoński W. Prognozy zachorowalności i umieralności na nowotwory złośliwe w Polsce do 2025 r. Krajowy Rejestr Nowotworów. Centrum Onkologii Instytutu im. M. Skłodowskiej-Curie : 45–51.
  4. Blamey RW, Cataliotti L. EUSOMA accreditation of breast units. Eur J Cancer. 2006; 42(10): 1331–1337.
  5. Jassem J, Krzakowski M, Potemski P, Warzocha K, Wysocki P. Rak piersi. In: Onkologia Kliniczna. Via Medica, Gdańsk 2015: 644.
  6. Górski B, Lubiński J. Test BRCA 1. Postępy Nauk Medycznych. 2008(7): 441–442.
  7. Górski B, Byrski T, Huzarski T, et al. Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. Am J Hum Genet. 2000; 66(6): 1963–1968.
  8. Grzybowska E, Zientek H, Jasinska A, et al. High frequency of recurrent mutations in BRCA1 and BRCA2 genes in Polish families with breast and ovarian cancer. Hum Mutat. 2000; 16(6): 482–490, doi: 10.1002/1098-1004(200012)16:6<482::AID-HUMU5>3.0.CO;2-O.
  9. Górski B, Jakubowska A, Huzarski T, et al. A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int J Cancer. 2004; 110(5): 683–686.
  10. Lubiński J, Górski B, Huzarski T, et al. BRCA1-positive breast cancers in young women from Poland. Breast Cancer Res Treat. 2006; 99(1): 71–76.
  11. Marcus JN, Watson P, Page DL, et al. Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer. 1996; 77(4): 697–709, doi: 10.1002/(sici)1097-0142(19960215)77:4<697::aid-cncr16>3.0.co;2-w.
  12. Martin AM, Blackwood MA, Antin-Ozerkis D, et al. Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic. J Clin Oncol. 2001; 19(8): 2247–2253.
  13. Loman N, Johannsson O, Bendahl P, et al. Prognosis and clinical presentation of BRCA2-associated breast cancer. Eur J Cancer. 2000; 36(11): 1365–1373.
  14. Antoniou AC, Pharoah PDP, Narod S, et al. Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet. 2005; 42(7): 602–603.
  15. Gronwald J, Huzarski T, Byrski B, et al. Cancer risks in first degree relatives of BRCA1 mutation carriers: effects of mutation and proband disease status. J Med Genet. 2006; 43(5): 424–428.
  16. Risinger JI, Berchuck A, Kohler MF, et al. Mutations of the E-cadherin gene in human gynecologic cancers. Nat Genet. 1994; 7(1): 98–102.
  17. Thorlacius S, Struewing JP, Hartge P, et al. Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet. 1998; 352(9137): 1337–1339.
  18. Krzemieniecki K, Jassem J, Krzakowski M. Szczególne sytuacje kliniczne. In: Rak sutka. Via Medica, Gdańsk 2014: 238.
  19. Brenner DJ. Contralateral second breast cancers: prediction and prevention. J Natl Cancer Inst. 2010; 102(7): 444–445.
  20. Filippakis GM, Georgiadou D, Pararas N, et al. Synchronous bilateral breast cancer with different biological profile and estrogen-progesterone receptor status. Breast J. 2008; 14(2): 209–210.
  21. Jeziorski A, Piekarski J. Bilateral breast cancer-current state knowledge. Onkol Pol. 1998; 1(3-4): 143–147.
  22. Verdecchia A, Francisci S, Brenner H, et al. EUROCARE-4 Working Group. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol. 2007; 8(9): 784–796.
  23. Berrino F, Angelis RDe, Sant M, et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–99: results of the EUROCARE-4 study. Lancet Oncol. 2007; 8(9): 773–783.
  24. Brenner H, Engelsmann B, Stegmaier C, et al. Clinical epidemiology of bilateral breast cancer. Cancer. 1993; 72(12): 3629–3635, doi: 10.1002/1097-0142(19931215)72:12<3629::aid-cncr2820721213>3.0.co;2-t.
  25. Góźdź S, Smok-Kalwat J, et al. Przeżycia pacjentek z dwustronnym rakiem sutka. Nowotwory. 2002; 53: 6.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl